Vir Biotechnology, Inc. VIR NASDAQ

Vir Biotechnology, Inc. (VIR) reported total assets of $1B and total liabilities of $237.55M for fiscal year 2025, resulting in total equity of $765.28M.

The company held $462.86M in cash and short-term investments. Total debt stood at $186.91M, with net debt of $-47.2M. The Debt-to-Equity (D/E) ratio was 0.24 (conservative).

Current ratio is 5.54, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0.24, current ratio of 5.54 — balance sheet is strong
• MOAT (47/100) — Total assets $1B and equity $765.28M support the company's competitive scale
• VALUE (100/100) — Debt-to-Equity 0.24 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 56/100 with 3/7 criteria passed.

KRTX

Karuna Therapeutics, Inc.

$329.83

+0.03%

MDGL

Madrigal Pharmaceuticals, Inc.

$524.99

-0.13%

BPMC

Blueprint Medicines Corporation

$129.46

+0.14%

KRYS

Krystal Biotech, Inc.

$270.00

+0.97%

RETA

Reata Pharmaceuticals, Inc.

$172.36

+0.02%

PTCT

PTC Therapeutics, Inc.

$73.01

+3.68%

ISEE

IVERIC bio, Inc.

$39.95

+0.38%

TERN

Terns Pharmaceuticals, Inc.

$52.68

+0.13%